STERIS (NYSE:STE) Director Cynthia Feldmann Sells 3,098 Shares

STERIS plc (NYSE:STE) Director Cynthia Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director directly owned 705 shares in the company, valued at approximately $167,233.05. This represents a 81.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

STERIS Stock Down 3.4%

STE stock traded down $8.02 during midday trading on Friday, hitting $230.49. The company’s stock had a trading volume of 983,236 shares, compared to its average volume of 793,669. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The company’s fifty day moving average price is $254.86 and its 200 day moving average price is $251.61. The stock has a market capitalization of $22.60 billion, a P/E ratio of 32.15 and a beta of 1.05. STERIS plc has a twelve month low of $204.90 and a twelve month high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same quarter in the previous year, the firm earned $2.32 earnings per share. The firm’s revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, equities research analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

Hedge Funds Weigh In On STERIS

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of STERIS by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after acquiring an additional 73,014 shares in the last quarter. State Street Corp boosted its position in shares of STERIS by 6.0% during the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after purchasing an additional 260,001 shares in the last quarter. Geode Capital Management LLC grew its stake in STERIS by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after purchasing an additional 14,151 shares during the period. Orbis Allan Gray Ltd increased its holdings in STERIS by 5.6% in the fourth quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after purchasing an additional 120,200 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in STERIS by 37.2% in the fourth quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock worth $411,522,000 after purchasing an additional 440,164 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.20.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.